Sierra Oncology Inc
NASDAQ:SRRA
Sierra Oncology Inc
Research & Development
Sierra Oncology Inc
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sierra Oncology Inc
NASDAQ:SRRA
|
Research & Development
-$70.8m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Zymeworks Inc
NYSE:ZYME
|
Research & Development
-$143.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Research & Development
-$131.8m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Research & Development
-$70.1m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$42m
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-32%
|
|
Spectral Medical Inc
TSX:EDT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Sierra Oncology Inc's Research & Development?
Research & Development
-70.8m
USD
Based on the financial report for Mar 31, 2022, Sierra Oncology Inc's Research & Development amounts to -70.8m USD.
What is Sierra Oncology Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-15%
Over the last year, the Research & Development growth was -49%. The average annual Research & Development growth rates for Sierra Oncology Inc have been -18% over the past three years , -15% over the past five years .